Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States

Journal of Pediatrics

Volumn 162, Issue 6, 2013, Pages

  Kavcic, Marko ^a   Fisher, Brian T ^a   Seif, Alix E ^a   Li, Yimei ^a   Huang, Yuan Shung ^a   Walker, Dana ^a   Aplenc, Richard ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ADENOVIRUS INFECTION; ADOLESCENT; ARTICLE; ASPERGILLOSIS; AUTOIMMUNE DISEASE; BACTEREMIA; CANDIDIASIS; CHILD; CYTOMEGALOVIRUS INFECTION; DRUG USE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HERPES ZOSTER; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; IMMUNE DEFICIENCY; INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYCOSIS; PEDIATRIC HOSPITAL; PHARMACOEPIDEMIOLOGY; PNEUMOCYSTIS PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEPSIS; SEPTIC SHOCK; UNITED STATES;

EID: 84880571791     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2012.11.038     Document Type: Article

References (22)

1. Solal-Céligny P. Safety of rituximab maintenance therapy in follicular lymphomas. Leuk Res 2006;30(Suppl 1):S16-S21.
2. Willems M, Haddad E, Niaudet P. Rituximab therapy for childhoodonset systemic lupus erythematosus. J Pediatr 2006;148:623-7.
3. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-908.
4. Grim SA, Pham T, Thielke J, Sankary H, Oberholzer J, Benedetti E, et al. Infectious complications associated with the use of rituximab for ABOincompatible and positive cross-match renal transplant recipients. Clin Transplant 2007;21:628-32.
5. Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007;48:1307-12.
6. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113: 4834-40.
7. Teichmann LL, Woenckhaus M, Vogel C, Salzberger B, Scholmerich J, Fleck M. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology 2008;47:1256-7.
8. van Vollenhoven RF, Ezery P, Bingham CO, Keystone EC, Fleischmann R, Furst DE, et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010;37:558-67.
9. US Food and Drug Administration. FDA warns of safety concern regarding rituxan in new patient population. Available from: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2006/ucm108810.htm. Accessed February 15, 2012.
10. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007;123:66-73.
11. Lund FE, Hollifield M, Schuer K, Lines JL, Randall TD, Garvy BA. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 2006;176:6147-54.
12. Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E, et al. Delayed- onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006;47:1013-7.
13. Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 2011;15:e2-16.
14. Vidal L, Gafter-Gvili A, Leibovici L, Shpilberg O. Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database Syst Rev 2009;CD006552.
15. El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, et al. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr 2007;150:376-82.
16. Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol 2010;28:3115-21.
17. Bennett CM. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006; 107:2639-42.
18. Hugle B, Solomon M, Harvey E, James A, Wadhwa A, Amin R, et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res 2010;62:1661-4.
19. Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 2011; 29:814-24.
20. Li Q, Teitz-Tennenbaum S, Donald EJ, Li M, Chang AE. In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol 2009;183:3195-203.
21. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 2008;18:11-8.
22. O'Malley KJ, Cook KF, Price MD, Wildes KR, Hurdle JF, Ashton CM. Measuring diagnoses: ICD code accuracy. Health Serv Res 2005;40: 1620-39.